GENELUX Corp — Investor Relations & Filings
Genelux Corporation is a clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for patients with aggressive and difficult-to-treat solid tumors. The company's technology is based on a proprietary discovery platform, CHOICE™, which utilizes an engineered vaccinia virus (VACV) as its backbone. This approach creates "off-the-shelf" therapeutics designed to selectively replicate within and kill cancer cells, stimulating a robust, patient-specific anti-tumor immune response. The lead product candidate, Olvi-Vec, is a modified vaccinia virus administered systemically. It is currently being evaluated in a registrational Phase 3 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer. The company is also preparing for a Phase 2 trial in recurrent non-small cell lung cancer.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - GENELUX Corp (0001231457) (Filer) | 2026-04-29 | English | |
| DEF 14A - GENELUX Corp (0001231457) (Filer) | 2026-04-29 | English | |
| 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | |
| 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | |
| 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | |
| 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 38557262 | ARS - GENELUX Corp (0001231457) (Filer) | 2026-04-29 | English | ||
| 38550613 | DEF 14A - GENELUX Corp (0001231457) (Filer) | 2026-04-29 | English | ||
| 33052416 | 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | ||
| 33052413 | 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | ||
| 33052411 | 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | ||
| 33052412 | 4 - GENELUX Corp (0001231457) (Issuer) | 2026-03-26 | English | ||
| 32989895 | 424B5 - GENELUX Corp (0001231457) (Filer) | 2026-03-19 | English | ||
| 32989872 | S-8 - GENELUX Corp (0001231457) (Filer) | 2026-03-19 | English | ||
| 32989612 | 8-K - GENELUX Corp (0001231457) (Filer) | 2026-03-19 | English | ||
| 32889064 | 4 - GENELUX CORP (0001231457) (Filer) | 2026-03-04 | English | ||
| 28486065 | 8-K Filing | 2026-02-02 | English | ||
| 28485668 | 8-K Filing | 2026-01-08 | English | ||
| 28485632 | 424B5 Filing | 2026-01-08 | English | ||
| 28485717 | 424B5 Filing | 2026-01-07 | English | ||
| 28485646 | 4 Filing | 2026-01-07 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Indivior PLC
Pharmaceutical company developing medicines for substance u…
|
INDV | GB | Manufacturing |
|
Indoco Remedies Ltd.
Integrated pharmaceutical company producing finished dosage…
|
INDOCO | IN | Manufacturing |
|
Indofarma Tbk.
A pharmaceutical and medical device company manufacturing a…
|
INAF | ID | Manufacturing |
|
Ind-Swift Laboratories Ltd.
Global manufacturer of APIs and intermediates across divers…
|
INDSWFTLAB | IN | Manufacturing |
|
Infant Bacterial Therapeutics
Develops microbiome drugs to prevent or treat rare diseases…
|
IBT | SE | Manufacturing |
|
Influx Healthtech Limited
CDMO specializing in nutraceuticals, health supplements, an…
|
INFLUX | IN | Manufacturing |
|
Inhibikase Therapeutics, Inc.
Develops kinase inhibitors for neurodegenerative and rare c…
|
IKT | US | Manufacturing |
|
Inhibrx Biosciences, Inc.
A clinical-stage biopharma company developing biologic ther…
|
INBX | US | Manufacturing |
|
InMed Pharmaceuticals Inc.
Develops cannabinoid-based drugs and manufactures rare cann…
|
INM | CA | Manufacturing |
|
Inmune Bio, Inc.
A clinical-stage biotech reprogramming the immune system to…
|
INMB | US | Manufacturing |
GENELUX Corp via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33857/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33857 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33857 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33857 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33857}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GENELUX Corp (id: 33857)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.